What's in Claes-Göran Östenson's pipeline?

Claes-Göran Östenson has 1 drugs in our index: 0 marketed, 0 filed, 0 in Phase 3, 1 in Phase 2, 0 in Phase 1.

Which companies overlap with Claes-Göran Östenson's portfolio?

Top competitors by shared drug class: AbbVie (prior sponsor, Abbott), Alizyme, Allergan, Gan and Lee Pharmaceuticals, USA, GlaxoSmithKline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/claes-g-ran-stenson.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Claes-Göran Östenson — Portfolio Competitive Intelligence Brief

Claes-Göran Östenson pipeline: 0 marketed, 0 filed, 0 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 0 Phase 3 1 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

No leading-phase drugs tracked for this sponsor.

Therapeutic area mix

Diabetes · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

AbbVie (prior sponsor, Abbott) · 1 shared drug class
Alizyme · 1 shared drug class
Allergan · 1 shared drug class
Gan and Lee Pharmaceuticals, USA · 1 shared drug class
GlaxoSmithKline · 1 shared drug class
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. · 1 shared drug class
Merck Sharp & Dohme LLC · 1 shared drug class
Novo Nordisk A/S · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Claes-Göran Östenson:

Cite this brief

Drug Landscape (2026). Claes-Göran Östenson — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/claes-g-ran-stenson. Accessed 2026-05-16.